De behandelingskeuze bij het gelokaliseerde prostaatcarcinoom

Delen via:

Log hier in om volledige toegang te krijgen.

Login of Account maken

 



Bronnen:

  1. Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377:132-42.,Wallis CJD, Klotz L. Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377:1301-2. ,Wilt TJ, Andriole GL, Brawer MK. Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377:1302-3.,Bill-Axelson A, Holmberg L, Ruutu M, et al; SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708-17. ,Holmberg L, Bill-Axelson A, Helgesen F, et al; Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781-9.,Bannuru RR, Dvorak T, Obadan N, et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Ann Intern Med. 2011;155:171-8. ,Roach M 3rd, Ceron Lizarraga TL, Lazar AA. Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence? Int J Radiat Oncol Biol Phys. 2015;93:1064-70.,Wallis CJD, Saskin R, Choo R, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;70:21-30. ,Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502. ,Hamdy FC, Donovan JL, Lane JA, et al; ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375:1415-24. ,Frank SJ, Pisters LL, Davis J, et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007;177:2151-6.,Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435-48. ,Johansson E, Steineck G, Holmberg L, et al; SPCG-4 Investigators. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12:891-9.,Sharma V, Karnes RJ. Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377:1302. ,Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-101,Shaverdian N, Verruttipong D, Wang PC, et al. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017;97:516-25.,Hoffman RM, Lo M, Clark JA, et al. Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. J Clin Oncol. 2017;35:2306-14.

Vici-beurs voor onderzoek naar sarcomen

feb 2017

Lees meer over Vici-beurs voor onderzoek naar sarcomen

Dendritische celvaccinatie bij melanoompatiënten

feb 2017 | Dermato-oncologie

Lees meer over Dendritische celvaccinatie bij melanoompatiënten

Betere behandeling van prostaatkanker door combinatie van bestralingstechnieken

feb 2017 | Radiotherapie, Uro-oncologie

Lees meer over Betere behandeling van prostaatkanker door combinatie van bestralingstechnieken

Jaarlijkse longkankerscreening is kosteneffectief en kan veel sterfgevallen voorkomen

feb 2017 | Longoncologie

Lees meer over Jaarlijkse longkankerscreening is kosteneffectief en kan veel sterfgevallen voorkomen

Europese goedkeuring pembrolizumab bij NSCLC met tumor-PD-L1 expressie ≥ 50%

feb 2017 | Longoncologie

Lees meer over Europese goedkeuring pembrolizumab bij NSCLC met tumor-PD-L1 expressie ≥ 50%

Gestage groei aantal patiënten met kanker in Nederland

feb 2017 | Borstkanker, Longoncologie, Maag-darm-leveroncologie

Lees meer over Gestage groei aantal patiënten met kanker in Nederland